Mark J. Ratain to Sulfonamides
This is a "connection" page, showing publications Mark J. Ratain has written about Sulfonamides.
Connection Strength
1.192
-
Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7.
Score: 0.391
-
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther. 2018 06; 103(6):956-958.
Score: 0.126
-
Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260.
Score: 0.117
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.103
-
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72.
Score: 0.102
-
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
Score: 0.095
-
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
Score: 0.093
-
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522.
Score: 0.090
-
Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
Score: 0.075